This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Investors Cheer Brown's Win

BOSTON ( TheStreet) -- The election of underdog Republican Scott Brown to the open U.S. Senate seat in Massachusetts Tuesday night greatly reduces the odds that health care reform will pass Congress and could extend a rally in health care stocks.

Brown's victory over Democrat Martha Coakley for the Bay State Senate seat vacated by the death of liberal lion Sen. Edward Kennedy gives Republicans 41 seats in the U.S. Senate. With those numbers, Republicans have the votes needed to break the Democrats' 60-seat majority and force major changes, or even stop completely, President Barack Obama's health care reform proposals.

The demise of health care reform is likely to be seen as a net positive for the health care sector, with investors expected to buying into the sector Wednesday.

"We expect the broad health care rally to continue, given that many generalists perceive Obamacare as unfavorable to the sector. We would, however, specifically highlight the HMO stocks, which bear the greatest burden in the proposed legislation," said Monness Crespi Hardt health care analyst Avik Roy, in a note to clients Tuesday night.

Roy expects HMO stocks with the largest exposure to Medicare Advantage are best positioned for a rally with a Brown victory, including Humana (HUM - Get Report), Coventry (CVH), WellCare (WCG - Get Report), HealthNet (HNT - Get Report) and UnitedHealth (UNH - Get Report).

U.S. pharmaceutical stocks were already outperforming the broader S&P 500 since the fall. Brown's victory could extend that rally, says Bank of America/Merrill Lynch analyst Eric Lo.

"Failure for reform would remove any near-term [earnings] pressure and provide incremental cash flows for companies to return to shareholders or utilize for deals to bolster the pipeline," he writes Wednesday, adding that Bristol-Myers Squibb (BMY - Get Report) and Eli Lilly (LLY) have the most to gain due to their relative high exposure to government-related drug spending.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
HNT $64.90 1.20%
HUM $192.79 0.79%
UNH $123.16 0.95%
WCG $85.14 0.37%
AMGN $154.89 0.89%

Markets

DOW 17,734.22 +114.71 0.65%
S&P 500 2,072.85 +9.74 0.47%
NASDAQ 5,002.8880 +16.0210 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs